Gallium labelled-prostate-specific membrane antigen-positron emission tomography/computed tomography (GA-PSMA-PET/CT) vs. choline-PET/CT in malignant prostate cancer: a systematic review

By:

Moghul, M

Contributor(s):

Publication details: 2017Uniform titles:

Journal of Endourology

Online resources:

Click here to access online

Summary: Introduction&Objective: Recently the role of Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) has become more prominent in helping to diagnose recurrent prostate cancer and malignant prostate cancer. The role of PSMA as a radiotracer appears to be surpassing that of choline tracers in prominent centres. We have evaluated current data regarding the use of PSMA-PET/CT scans compared to Choline PET/CT scans. Materials and Methods: We performed a review of PubMed/Medline, Clinical trials.gov and the Cochrane Library in March 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Results: 4 studies were included in this review having directly compared 68GA-PSMA-PET/CT and Choline PET/CT scans. Choline tracers used were 11C in one study and 18F in the other studies. Overall 230 men had both 68GA-PSMA PET and choline-PET/CT scans. Overall detection rates for biochemical recurrence were 81.1% for GA-PSMA-PET and 70.3% for choline-PET/CT. This indicates that GA-PSMA PET/CT is significantly better than choline-PET/CT for detecting recurrence of prostate cancer (P < 0.005). 68GA-PSMA-PET/CT also showed higher detection rates at lower PSA values. Lesions missed on PSMAPET/CT but captured by choline-PET/CT were found to be negligible (1-2%). Conclusions: 68GA-PSMA-PET/CT appears to offer better diagnostic capability than choline-PET/CT, as well as similar if not higher sensitivities and specificities, indicating justification for replacing choline as the radiotracer of choice in prostate cancer and guiding further management decisions. [Conference abstract]

Holdings
Item type	Home library	Collection	Class number	Status	Date due	Barcode
Book	Ferriman information and Library Service (North Middlesex) Shelves	Staff publications for NMDX		Available

NMUH Staff Publications

EMBASE

Introduction&amp;Objective: Recently the role of Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) has become more prominent in helping to diagnose recurrent prostate cancer and malignant prostate cancer. The role of PSMA as a radiotracer appears to be surpassing that of choline tracers in prominent centres. We have evaluated current data regarding the use of PSMA-PET/CT scans compared to Choline PET/CT scans. Materials and Methods: We performed a review of PubMed/Medline, Clinical trials.gov and the Cochrane Library in March 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Results: 4 studies were included in this review having directly compared 68GA-PSMA-PET/CT and Choline PET/CT scans. Choline tracers used were 11C in one study and 18F in the other studies. Overall 230 men had both 68GA-PSMA PET and choline-PET/CT scans. Overall detection rates for biochemical recurrence were 81.1% for GA-PSMA-PET and 70.3% for choline-PET/CT. This indicates that GA-PSMA PET/CT is significantly better than choline-PET/CT for detecting recurrence of prostate cancer (P &lt; 0.005). 68GA-PSMA-PET/CT also showed higher detection rates at lower PSA values. Lesions missed on PSMAPET/CT but captured by choline-PET/CT were found to be negligible (1-2%). Conclusions: 68GA-PSMA-PET/CT appears to offer better diagnostic capability than choline-PET/CT, as well as similar if not higher sensitivities and specificities, indicating justification for replacing choline as the radiotracer of choice in prostate cancer and guiding further management decisions.&nbsp;[Conference abstract]

There are no comments on this title.

to post a comment.